Derroche y daño en el tratamiento de la hipertensión leve / Iona Heath

The 2012 Cochrane Review on “Pharmacotherapy for Mild Hypertension” concluded that antihypertensive drugs used in the treatment of otherwise healthy adults with mild hypertension (systolic blood pressure [BP], 140-159 mm Hg, and/or diastolic BP, 90-99 mm Hg) have not been shown to reduce mortality or morbidity in randomized clinical trials. Will this landmark conclusion affect clinical practice and slow the inexorable expansion of disease categories? It certainly should because overdiagnosis and overtreatment are potent causes of both waste and harm and seem to be operating in the interests of the pharmaceutical industry rather than in those of the patients whom the industry claims to serve.

Quien es Iona Heath?
She worked as a GP in London since 1975 and retired 2010. She has held several roles in the Royal College of General Practitioners (RCGP) including chair of the Ethics Committee, the International Committee, and the Health Inequalities Standing Group. She was vice chair of the college and in 2009 was elected college president. She chaired the BMJ Ethics Committee 2004 to 2009 and writes a regular column for the BMJ.

Sacarse el sombrero con esta señora y luego ponerse a leer y pensar en los excesos que podemos cometer.

Compartiremos con ella el taller sobre Prevención Cuaternaria que coordina Marc Jamoulle en la Conferencia Mundial de WONCA en Praga:
"Quaternary prevention, addressing the limits of medical practice"
authors: M. Jamoulle, G. Tsoi, I. Heath, D. Mangin, M. Z. Pezeshki, M. Pizzanelli Báez, A.L. Silva, J. Bernstein. Presenting author: M. Jamoulle, G. Tsoi, I. Heath, D. Mangin, M.Z. Pezeshki, M. Pizzanelli Báez
Agendado:
Día: 26 de Junio, de 10.30 a 12.00

Para ver artículo: http://archinte.jamanetwork.com/article.aspx?articleid=1687525

el editor